Table 2.

Summary of published cases of COVID-19-induced SLE

Authors	Age in years and sex	Clinical presentation	Vaccine type	Appearing of symptoms after vaccine exposure	Investigations result	Therapeutic intervention	Serology result
Nune et al. [8]	24 male	Polyarthralgia Fever Fatigue Oral ulcer Lymphadenopathy	Pfizer-BioNTech SARS-CoV-2 vaccine	14 days after 2nd dose	Lymphopenia High CRP	GC, MTX	Positive ANA and anti-dsDNA low complements (C3&4) levels
Patil and Patil [9]	22 female	Polyarthralgia Fever Skin rash Bipedal edema Lymphadenopathy Mild hepatomegaly	AstraZeneca COVID-19 vaccine	10 days after the 2nd dose	Thrombocytopenia Anemia Positive Direct Coombs test High ESR Proteinuria (300 mg/24 h)	GC, HCQ, MMF	Positive ANA and anti-dsDNA
Zavala-Miranda et al. [10]	23 female	Nephrotic syndrome Hair loss	AstraZeneca COVID-19 vaccine	7 days after the 1st dose	Lymphopenia Proteinuria (12.6 g/24 h) Renal biopsy showed class V lupus nephritis	GC, MMF, HCQ, Diuretics	Positive ANA and anti-dsDNA low complements (C3&4) levels
Current case	22 female	Skin rash Acute pancreatitis	Pfizer-BioNTech SARS-CoV-2 vaccine	7 days after the 1st dose	Lymphopenia Anemia Thrombocytopenia Positive Direct Coombs test High amylase and lipase High ESR	GC, HCQ, AZA	Positive ANA and anti-dsDNA low complements (C3&4) levels

CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; ANA, antinuclear antibodies; Anti-dsDNA, anti-double-stranded DNA antibody; GC, glucocorticoids; MTX, methotrexate; HCQ, hydroxychloroquine; MMF, mycophenolate mofetil; AZA, azathioprine